VikingInvest, I also appreciate your posts as well. I am ok with you having a different opinion than me. We are both speculating based upon the facts we know for sure.
I think we both would be happy with either scenario, as long as DCVax -L is approved in all 4 countries as soon as possible & becomes available to GBM patients as soon as possible.
I will stick with my opinion because: (1) Cognate is more ready & it has more production capacity than Advent, (2) I still believe that NWBio received SAP & revised endpoint buy-in from the FDA before they got buy-in from the EMA or MHRA, and that was the main reason it took so long to get data-lock, (3) Bethesda (NWBio) is a lot closer to Washington DC (FDA) than it is to London (MHRA) (I admit that this reason became less valid after COVID happened).
Thankfully, all of these questions will be answered soon.
Market Data 
Markets 
AI
